NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
LTM NOPAT
($194.7M)
NOPAT margin
(9.3%)
5Y avg: (118.3%)
EPV as % of EV
(8.4%)
Market-Implied Value of Growth,
MIVoG as % of EV
108.4%
Discount rate
6.6%
Stock quality
6/10
Good
ALNY Earnings Power Value Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY NOPAT
Crunching data... Almost there!
ALNY Earnings Power Value and Enterprise Value
Crunching data... Almost there!
ALNY vs Peer Set: Earnings Power Value comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc. Earnings Power Value?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Earnings Power Value is approximately ($2,949.0M).
What is Alnylam Pharmaceuticals, Inc. EV (Enterprise Value)?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Enterprise Value (EV) estimates at $34.9B.
What is Alnylam Pharmaceuticals, Inc. NOPAT?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Net operating profit after tax (NOPAT) is approximately ($194.7M).